CNS Pharmaceuticals effects 1-for-30 reverse stock split to meet Nasdaq listing requirement

CNS Pharmaceuticals, Inc.

Reverse stock split effective Nov 28, 2022 at 4:01 PM ET; trading on split-adjusted basis begins Nov 29, 2022.
Outstanding shares reduced from ~40.03M to ~1.33M; authorized shares remain at 75M.
Purpose: increase per-share price to comply with Nasdaq minimum bid price requirement.
No fractional shares; rounding up to whole share; CUSIP changes to 18978H201.
Outstanding warrants, options, and RSUs adjusted proportionally; par value unchanged at $0.001.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CNS Pharmaceuticals, Inc.: Approved amendment to articles of incorporation to effect a 1-for-30 reverse stock split (effective 2022-11-28).

Change: charter amendment
Effective: 2022-11-28

Exact text from the filing

The Amendment was filed with the Secretary of State of the State of Nevada and the Reverse Stock Split will become effective in accordance with the terms of the Amendment at 4:01 p.m. Eastern Time on November 28, 2022 (the “Effective Time”).

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

CNS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.